Key Details
Price
$1.21Annual Revenue
$78.12 MAnnual EPS
-$2.02Annual ROE
-43.17%Beta
1.90Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 04, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.
Editas Medicine said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's transition towards becoming a developer of therapies that edit genes within the body.
CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced a critical pivot to optimize its cost structure, extend its cash runway into Q2 2027, and position the Company to accelerate its intent to achieve in vivo human proof of concept in approximately two years.
Editas Medicine, Inc. (NASDAQ:EDIT ) 7th Annual Evercore HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Erick Lucera - Executive Vice President and Chief Financial Officer Cristi Barnett - Senior Vice President, Corporate Communications and Investor Relations Conference Call Participants Liisa Bayko - Evercore ISI Liisa Bayko Okay, welcome everyone. This is Evercore's Healthcare Conference.
Editas Medicine, Inc. (NASDAQ:EDIT ) Stifel 2024 Healthcare Conference November 19, 2024 1:50 PM ET Company Participants Erick Lucera - Chief Financial Officer Conference Call Participants Dae Gon Ha - Stifel Dae Gon Ha All right. Thanks, everyone, for joining us for the next half hour.
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December:
EDIT reports mixed third-quarter 2024 results as earnings beat expectations while revenues miss the same.
Editas Medicine (EDIT) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.55 per share a year ago.
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.
FAQ
- What is the primary business of Editas Medicine?
- What is the ticker symbol for Editas Medicine?
- Does Editas Medicine pay dividends?
- What sector is Editas Medicine in?
- What industry is Editas Medicine in?
- What country is Editas Medicine based in?
- When did Editas Medicine go public?
- Is Editas Medicine in the S&P 500?
- Is Editas Medicine in the NASDAQ 100?
- Is Editas Medicine in the Dow Jones?
- When was Editas Medicine's last earnings report?
- When does Editas Medicine report earnings?
- Should I buy Editas Medicine stock now?